Pharmacogenomics in Alzheimer's disease
1EuroEspes Biomedical Research Center, Institute for CNS Disorders, Bergondo, Coruña, Spain.
Methods in Molecular Biology (Clifton, N.J.)
|March 29, 2008
Summary
Genetic factors significantly impact Alzheimer's disease (AD) drug response, with variations in genes like APOE and CYP2D6 affecting treatment efficacy. Personalized pharmacogenomic approaches are crucial for optimizing AD therapeutics and improving patient outcomes.
Area of Science:
- Neuroscience
- Genetics
- Pharmacology
Background:
- Alzheimer's disease (AD) pharmacological treatment is costly, with limited efficacy in many patients.
- AD pathogenesis and drug metabolism are complex, genetically regulated traits involving numerous genes.
- Genetic variations are more prevalent in AD patients, influencing disease progression and treatment response.
Purpose of the Study:
- To explore the role of pharmacogenetics and pharmacogenomics in Alzheimer's disease treatment.
- To identify genetic factors influencing variability in drug response and metabolism in AD patients.
- To highlight the potential of incorporating genetic information into clinical practice for optimized AD therapeutics.
Main Methods:
- Review of structural and functional genomics studies in AD.
- Analysis of pharmacogenomic data related to drug response and genetic variations.
- Investigation of gene-environment interactions, including APOE and CYP2D6 polymorphisms.
Main Results:
- Over 200 genes are implicated in AD pathogenesis.
- Therapeutic response to conventional AD drugs is genotype-specific, with APOE 4/4 carriers showing poorer outcomes.
- CYP2D6 genetic variants affect AD drug metabolism, with poor and ultrarapid metabolizers exhibiting reduced efficacy.
- Pharmacogenetic factors account for 60-90% of drug disposition and pharmacodynamics variability.
Conclusions:
- Genetic variations, including APOE and CYP2D6, significantly modulate AD drug efficacy and safety.
- Pharmacogenomic profiling can enable personalized treatment strategies for Alzheimer's disease.
- Integrating pharmacogenetic protocols into AD research and clinical practice is essential for developing cost-effective and effective therapies.
More Related Videos
09:33Quantitative 3D In Silico Modeling (q3DISM) of Cerebral Amyloid-beta Phagocytosis in Rodent Models of Alzheimer's Disease
Published on: December 26, 2016
04:22Biomarker Identification for Gender Specificity of Alzheimer's Disease Based on the Glial Transcriptome Profiles
Published on: May 20, 2024
Related Concept Videos
01:29Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
01:29Pharmacogenetics and Pharmacogenomics: Overview
Pharmacogenetics and pharmacogenomics examine how genetic factors influence an individual's response to drugs. While pharmacogenetics focuses on the impact of specific genetic variants on drug effects, pharmacogenomics takes a broader approach, studying how genetic variation across populations contributes to differences in drug responses. These fields aim to explain why individuals may experience varying levels of efficacy or adverse reactions to the same medication.Variability in drug...
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
01:27Pharmacogenetics of Drug Metabolism: Overview
Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
01:27Principles of Pharmacogenetics: Types of Genetic Variants
The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
01:27Pharmacodynamics in Geriatric Patients: Effects of Age
Age-related pharmacokinetic changes are extensively documented, but understanding age-related pharmacodynamic alterations is relatively limited. This knowledge gap can be partly attributed to the complexity of developing appropriate measures of drug responses compared to bioanalytical methods for determining drug concentrations.Most information regarding age-related differences in human pharmacodynamics originates from cross-sectional studies. However, these studies assume that observed mean...